visual blindness, olfactory loss, or hearing disturbance)
With mixed symptoms.Specify if:

Acute episode: symptoms present for less than six months
Persistent: symptoms present for six months or more.Specify if:

Psychological stressor (conversion disorder)
No psychological stressor (functional neurological symptom disorder)

Exclusion of neurological disease
Conversion disorder presents with symptoms that typically resemble a neurological disorder such as stroke, multiple sclerosis, epilepsy, hypokalemic periodic paralysis or narcolepsy. The neurologist must carefully exclude neurological disease, through examination and appropriate investigations. However, it is not uncommon for patients with neurological disease to also have conversion disorder.In excluding neurological disease, the neurologist has traditionally relied partly on the presence of positive signs of conversion disorder, i.e. certain aspects of the presentation that were thought to be rare in neurological disease but common in conversion. The validity of many of these signs has been questioned, however, by a study showing they also occur in neurological disease. One such symptom, for example, is la belle indifférence, described in DSM-IV as "a relative lack of concern about the nature or implications of the symptoms". In a later study, no evidence was found that patients with functional symptoms are any more likely to exhibit this than patients with a confirmed organic disease. In DSM-V, la belle indifférence was removed as a diagnostic criterion. Another feature thought to be important was that symptoms tended to be more severe on the non-dominant (usually left) side of the body.
If no response is seen or if inducers of caspofungin clearance (see above) are coadministered the daily dose may be increased to 70 mg. An infusion should take approximately 1 hour. Dosage forms
Cancidas 50 mg for intravenous infusion (manufacturer Merck)
Cancidas 70 mg for intravenous infusion (manufacturer Merck)
Brand names in countries other than the U.S. may vary. Semisynthesis
Caspofungin is semisynthesized from pneumocandin B0, a fermentation product of Glarea lozoyensis. References
External links
"Caspofungin". Drug Information Portal. U.S. National Library of Medicine. U.S. Full Prescribing Information
EMA on Cancidas (Summary of Product Characteristics)